Lebrikizumab improves anxiety and depression symptoms in adolescents with moderate-to-severe atopic dermatitis, with significant PROMIS score improvements after 52 weeks. The therapy enhances ...

Dupixent (dupilumab) – an IL-4 and IL-13 inhibitor – has dominated the market for biological therapies for atopic dermatitis since it was approved by the FDA in 2017.

Dupixent is clearly effective in a wide range of inflammation-related diseases. It is currently approved for certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal ...

SINGAPORE, May 14, 2025 /PRNewswire/ -- The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, ...

To assess the impact of food allergies on the progression of atopic dermatitis to other atopic disorders, researchers analyzed electronic health records from 10,688 children (57.5% boys ...

SINGAPORE, May 14, 2025 /PRNewswire/ -- The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive ...

Japan approved rozanolixizumab for self-administration in generalized myasthenia gravis, following the EU's lead, allowing home administration with professional training. The MycarinG study ...

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion in ...

You breathe the mist into your lungs. Your doctor will likely start by prescribing the recommended dosage of Breztri Aerosphere. They’ll monitor you to be sure it provides the desired effect.

Perioral dermatitis is a common inflammatory skin disease presenting as tiny papules or pustules localized around the mouth, nose, or eyes. It is often confused with acne vulgaris, rosacea ...

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...